Metformin
First-line diabetes medication now studied extensively for anti-aging and longevity effects beyond glucose control.
Evidence Summary
Metformin has decades of human safety data and remains first-line for type 2 diabetes. Its longevity signal comes from human observational/quasi-experimental data plus new preclinical work. A 2025 target-trial emulation (The Journals of Gerontology: Series A) in 438 propensity-matched women aged 60+ with type 2 diabetes found metformin initiators had a 30% lower risk of death before age 90 than sulfonylurea initiators (adjusted HR 0.70, 95% CI 0.56-0.88; 3.7 vs 5.0 deaths per 100 person-years). A landmark 2024 Cell study showed roughly three years (about 40 months) of metformin (20 mg/kg/day) in aged male cynomolgus monkeys reduced cellular senescence across multiple organs and left brain DNA-methylation age about 6 years younger than untreated animals, apparently via activation of the antioxidant regulator Nrf2 and largely independent of glucose lowering. The TAME trial, designed to test whether metformin delays age-related disease in non-diabetic older adults, remains the pivotal human test and has not yet reported. A 2025 review (Ageing Research Reviews) urges caution: benefit in already-healthy, insulin-sensitive, non-diabetic people is unproven, and metformin can blunt some exercise adaptations. Evidence is strongest for people with dysglycemia; use for healthy-aging is investigational and off-label. Educational information, not medical advice.
Evidence Scale
Mechanism of Action
Activates AMPK and inhibits mTOR signaling, reduces hepatic gluconeogenesis, and improves insulin sensitivity. Proposed geroprotective actions extend beyond glucose control: dampening of chronic inflammation, effects on the gut microbiome, reduced cellular senescence, and, as shown in 2024 primate work, activation of the antioxidant regulator Nrf2, which may reduce oxidative-stress-driven aging independent of blood-sugar lowering.
Who Is This For?
Pre-diabetes, metabolic syndrome, longevity optimization. Monitor B12 levels. Not for lean individuals with good insulin sensitivity.
Protocol & Dosing
Dose
500-2000mg daily, typically 500-1000mg for longevity purposes.
Frequency
Daily with meals
Duration
Ongoing
Protocol Summary
Oral tablets taken with meals; extended-release is preferred for GI tolerability. Physicians typically start low (500 mg) and titrate. For metabolic indications, 500-2000 mg/day; lower doses (500-1000 mg/day) are commonly used when the goal is metabolic or longevity optimization. Periodic vitamin B12 monitoring is advised. Because metformin may blunt some exercise-induced adaptations, timing and dosing around a training program should be individualized. Investigational and off-label for healthy-aging; use only under qualified physician supervision.
Latest Evidence
2024–2025: primate aging-clock + human longevity data
A 2024 Cell study followed aged male cynomolgus monkeys given metformin (20 mg/kg/day) for roughly three years. Treated animals showed reduced cellular senescence across lung, liver, kidney, heart, skin and brain, preserved frontal-lobe cortical thickness, and a brain DNA-methylation age about 6 years younger than controls, apparently via Nrf2 activation and largely independent of glucose lowering. In humans, a 2025 target-trial emulation in 438 matched women aged 60+ with type 2 diabetes found metformin initiators had a 30% lower risk of death before age 90 than sulfonylurea initiators (HR 0.70).
These are early and largely preclinical or observational findings; they do not establish that metformin extends lifespan in healthy people. Metformin for healthy-aging is investigational and off-label, used only under qualified physician supervision, and may blunt some exercise adaptations. The TAME trial remains the pivotal human test and has not yet reported. Educational information, not medical advice.
Latest Evidence · Human Data
Metformin vs. Sulfonylureas: Risk of Death Before Age 90
Adjusted hazard ratios; values below 1.0 favor metformin. Target-trial emulation, 438 propensity-matched women aged 60+ with type 2 diabetes. The Journals of Gerontology: Series A, 2025.
Related on Peak Human
Diabetes & Metabolic Health
Metformin is first-line for type 2 diabetes.
Optimization Service
Biomarker-tracked metabolic optimization at Peak Human.
Longevity
Physician-guided healthy-aging protocols.
Rapamycin
Often discussed alongside metformin as a geroprotector.
GLP-1 Agonists
Related metabolic interventions with human outcome data.
Longevity Research Insider
Weekly review of new longevity research.
Key references: Metformin decelerates aging clock in male monkeys — Cell (2024) · Metformin vs sulfonylureas & exceptional longevity — J Gerontol A (2025) · Emerging uncertainty on the anti-aging potential of metformin — Ageing Research Reviews (2025)
Interactions & Precautions
Contraindications
- Kidney disease (eGFR <30)
- Acute illness
- Alcohol abuse
- Contrast procedures
Potential Risks
- •Lactic acidosis (rare)
- •B12 deficiency
- •GI intolerance
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Extended-release reduces GI effects. Consider periodic B12 monitoring and supplementation. Metformin can blunt some exercise adaptations (muscle hypertrophy and mitochondrial/aerobic gains were reduced in some RCTs of older adults), so coordinate dosing with training goals. The 2024 primate data and 2025 human longevity signal are encouraging but not confirmatory; TAME will help clarify benefit in non-diabetics. Reserve strongest enthusiasm for patients with dysglycemia or metabolic syndrome.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation